For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
40
views
84
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      243
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts

      review-article
      Author(s): , MD, M.Sc p1 , p2 , p3 , , MD, PhD p1 , p2 , , MD, PhD p1 , p2 , p4 , , BSc, MBBS p1 , p2
      Publication date (Electronic):
      Journal: JNCI Cancer Spectrum
      Publisher: Oxford University Press

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          No validated molecular biomarkers exist to help guide diagnosis of renal cell carcinoma (RCC) patients. We seek to evaluate the quality of published RCC circulating diagnostic biomarker manuscripts using the Standards for Reporting of Diagnostic Accuracy Studies (STARD) guidelines.

          Methods

          The phrase “(renal cell carcinoma OR renal cancer OR kidney cancer OR kidney carcinoma) AND circulating AND (biomarkers OR cell free DNA OR tumor DNA OR methylated cell free DNA OR methylated tumor DNA)” was searched in Embase, MEDLINE, and PubMed in March 2018. Relevant manuscripts were scored using 41 STARD subcriteria for a maximal score of 26 points. All tests of statistical significance were 2 sided.

          Results

          The search identified 535 publications: 27 manuscripts of primary research were analyzed. The median STARD score was 11.5 (range = 7-16.75). All manuscripts had appropriate abstracts, introductions, and distribution of alternative diagnoses. None of the manuscripts stated how indeterminant data were handled or if adverse events occurred from performing the index test or reference standard. Statistically significantly higher STARD scores were present in manuscripts reporting receiver operator characteristic curves ( P < .001), larger sample sizes ( P = .007), and after release of the original STARD statement ( P = .005).

          Conclusions

          Most RCC circulating diagnostic biomarker manuscripts poorly adhere to the STARD guidelines. Future studies adhering to STARD guidelines may address this unmet need.

          Related collections

          Most cited references84

          • Record: found
          • Abstract: found
          • Article: not found

          The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

          Alessandro Liberati, Douglas G. Altman, Jennifer Tetzlaff … (2010)
          Systematic reviews and meta-analyses are essential to summarise evidence relating to efficacy and safety of healthcare interventions accurately and reliably. The clarity and transparency of these reports, however, are not optimal. Poor reporting of systematic reviews diminishes their value to clinicians, policy makers, and other users. Since the development of the QUOROM (quality of reporting of meta-analysis) statement—a reporting guideline published in 1999—there have been several conceptual, methodological, and practical advances regarding the conduct and reporting of systematic reviews and meta-analyses. Also, reviews of published systematic reviews have found that key information about these studies is often poorly reported. Realising these issues, an international group that included experienced authors and methodologists developed PRISMA (preferred reporting items for systematic reviews and meta-analyses) as an evolution of the original QUOROM guideline for systematic reviews and meta-analyses of evaluations of health care interventions. The PRISMA statement consists of a 27-item checklist and a four-phase flow diagram. The checklist includes items deemed essential for transparent reporting of a systematic review. In this explanation and elaboration document, we explain the meaning and rationale for each checklist item. For each item, we include an example of good reporting and, where possible, references to relevant empirical studies and methodological literature. The PRISMA statement, this document, and the associated website (www.prisma-statement.org/) should be helpful resources to improve reporting of systematic reviews and meta-analyses.
          Article 0 comments Cited 3644 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.

            Hadi Valadi, Karin Ekström, Apostolos Bossios … (2007)
            Exosomes are vesicles of endocytic origin released by many cells. These vesicles can mediate communication between cells, facilitating processes such as antigen presentation. Here, we show that exosomes from a mouse and a human mast cell line (MC/9 and HMC-1, respectively), as well as primary bone marrow-derived mouse mast cells, contain RNA. Microarray assessments revealed the presence of mRNA from approximately 1300 genes, many of which are not present in the cytoplasm of the donor cell. In vitro translation proved that the exosome mRNAs were functional. Quality control RNA analysis of total RNA derived from exosomes also revealed presence of small RNAs, including microRNAs. The RNA from mast cell exosomes is transferable to other mouse and human mast cells. After transfer of mouse exosomal RNA to human mast cells, new mouse proteins were found in the recipient cells, indicating that transferred exosomal mRNA can be translated after entering another cell. In summary, we show that exosomes contain both mRNA and microRNA, which can be delivered to another cell, and can be functional in this new location. We propose that this RNA is called "exosomal shuttle RNA" (esRNA).
            Article 0 comments Cited 2434 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

              Kenneth F Schulz, Douglas G. Altman, David Moher … (2010)
              The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience
              Article 0 comments Cited 1703 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): JNCI Cancer Spectr
                Journal ID (iso-abbrev): JNCI Cancer Spectr
                Journal ID (publisher-id): jncics
                Title: JNCI Cancer Spectrum
                Publisher: Oxford University Press
                ISSN (Electronic): 2515-5091
                Publication date Collection: October 2020
                Publication date (Electronic): 08 June 2020
                Publication date PMC-release: 08 June 2020
                Volume: 4
                Issue: 5
                Electronic Location Identifier: pkaa050
                Affiliations
                [p1 ] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario, Canada
                [p2 ] University of Toronto , Toronto, Ontario, Canada
                [p3 ] Division of Oncology, William Osler Health System , Brampton, Ontario, Canada
                [p4 ] Livestrong Cancer Institute and Dell Medical School, University of Texas at Austin , Austin, TX, USA
                Author notes
                Correspondence to: Aaron R. Hansen, MBBS, FRACP, 700 University Ave, 7-623 Toronto, Ontario, M5G 1Z6, Canada (e-mail: aaron.hansen@ 123456uhn.ca ).
                Author information
                http://orcid.org/0000-0002-2569-3275
                Article
                Publisher ID: pkaa050
                DOI: 10.1093/jncics/pkaa050
                PMC ID: 7583155
                SO-VID: 6c160973-8788-4e81-a8dd-02c0b094ef6a
                Copyright © © The Author(s) 2020. Published by Oxford University Press.
                License:

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                Date received : 19 February 2019
                Date revision received : 14 May 2020
                Date accepted : 01 June 2020
                Page count
                Pages: 11
                Categories
                Subject: Review
                Subject: AcademicSubjects/MED00010

                Data availability:

                Comments

                Comment on this article